The U.S. Food and Drug Administration (FDA) on Thursday issued recommendations to vaccine manufacturers regarding the virus strains to be included in influenza vaccines for the 2025-2026 flu season. The selection is based on global surveillance data and expert analysis to ensure optimal protection against anticipated flu variants.

These recommendations will guide pharmaceutical companies in developing and producing vaccines aimed at reducing the impact of seasonal influenza. Health officials emphasize the importance of timely vaccinations to prevent widespread outbreaks and protect public health